RxDoctor Payments Data

Lakeshia Yarbrough

Family · Mc Kenzie, TNNPI 1275208829

Payments from drug & device makers

$3,437in general payments, 2019–2025

Across 167 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$591
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$516
  • Novartis$373
  • Novo Nordisk$276
  • Merck$264
  • Philips North America LLC$251
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,437 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,599
Medicare patients
64
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban69$77,571
Repatha SureclickEvolocumab50$47,849
EntrestoSacubitril/Valsartan44$42,483
EliquisApixaban26$31,811
VascepaIcosapent Ethyl42$19,397
FarxigaDapagliflozin Propanediol25$17,695
Ranolazine ErRanolazine40$3,832
Midodrine Hcl14$2,044
Amiodarone Hcl49$1,961
Potassium Chloride90$1,876
Atorvastatin Calcium150$1,727
Metoprolol Succinate87$1,296
Hydralazine Hcl39$1,041
Isosorbide Mononitrate ErIsosorbide Mononitrate64$801
Rosuvastatin Calcium57$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$98$77,57169 claims
NovartisEntresto$373$42,48344 claims
AstraZenecaFarxiga$158$17,69525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Mc Kenzie

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →